Connect with us
Prague Gaming & TECH Summit 2024

Artificial Intelligence

NovoBiome launched to revolutionize treatment of liver diseases by targeting the microbiome-gut-liver axis

Published

on

NovoBiome launched to revolutionize treatment of liver diseases by targeting the microbiome-gut-liver axis

First biotech company dedicated to developing breakthrough Live Biotherapeutic Products targeting the critical nexus of liver, intestinal diseases and gut microbiome

Lead product focused on NAFLD / NASH, the third wave in metabolic diseases after obesity and Type 2 diabetes

Disruptive and comprehensive ex-vivo research and discovery platform in development to analyze the symbiotic relationships between microbiota and the human intestine

Paris, France – 04 May 2021: NovoBiome (“the Company”), a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome, has been launched today by a team of world-leading experts in the fields of Microbiology and Artificial Intelligence. The new company will develop breakthrough Live Biotherapeutics Products (LBPs)1 targeting the microbiome-gut-liver axis. NovoBiome is building a comprehensive, disruptive ex-vivo research and discovery platform to analyze the symbiotic relationship between the microbiota and the human intestine.

NovoBiome’s first LBP drug candidate, ADC-001, targets potential first-in-class therapies for hepatic conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). NAFLD has become the most common cause of chronic liver diseases, and can lead to NASH, a more serious condition. Due to the growing epidemic of metabolic disorders with the development of Western lifestyles, the NASH market is rising rapidly and is expected to reach $18.3 billion by 2026 in the US and Europe’s 5 largest markets, a CAGR of 63% from 20162. The NASH market is seen as the third wave in metabolic diseases, after the rise of obesity and Type 2 diabetes. ADC-001 comprises an anti-inflammatory bacterium, member of the class Coriobacteriia that has demonstrated potent therapeutic effects in vitro and in animal models. It is currently in development with the aim of entering human trials by 2022-2023.

NovoBiome is building a disruptive, ex-vivo research and discovery platform, NovoSift®, designed to mimic human intestinal physiology that will unlock new insights into disease pathophysiology, novel drug targets, compounds and LBP drug candidates. The platform brings together four best-in-class technologies, all of which have separately been nominated “Method of the Year” by Nature Magazine: high-throughput functional metagenomics, human intestinal organoids, high resolution fluorescent confocal microscopy and a deep learning AI algorithm.

NovoBiome was co-founded by world-leading experts in Microbiome research and AI and is led by Pierre Pierre-Yves Mousset, Chief Executive Officer; Hervé Blottière, Chief Scientific Officer; Olivier Tastet, Chief AI Officer; and Joël Doré, Senior Scientific Consultant.

Pierre-Yves Mousset, Chief Executive Officer of NovoBiome, said: “The microbiome is a fast growing and disruptive field of research that has the potential to revolutionize the diagnosis, prevention and treatment of liver diseases. NovoBiome has been founded to exploit the broad potential of LBPs that target the critical microbiome-gut-liver axis. The role of gut bacteria in the large and growing NAFLD and NASH markets has been clearly documented and NovoBiome aims to provide the first ecosystem treatment approach. With a strong founding team, excellent science, best-in-class technologies and enthusiastic support from investors, we are well positioned to become a leader in discovering next-generation gut-liver therapies.”

-End-

About NovoBiome

NovoBiome is a drug discovery company focused on the critical nexus of liver, intestinal diseases and the gut microbiome. It is developing breakthrough Live Biotherapeutics Products (LBPs), a novel and emerging class of drugs containing living micro-organisms that have a positive influence on the health and physiology of the host. NovoBiome’s first LBP drug candidate, ADC-001, targets potential first-in-class therapies for hepatic conditions such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). The Company is developing an ex-vivo research and discovery platform, NovoSift®, designed to mimic human intestinal physiology that will unlock new insights into disease pathophysiology, novel drug targets, compounds and LBP drug candidates.

NovoBiome is headquartered in France. For more information, please visit: www.novobiome.eu

About the NovoBiome team

Pierre-Yves Mousset studied medicine at the Pitié-Salpétrière faculty (Sorbonne University – Paris). After two decades spent as a medical director and then managing director in health communications and marketing agencies, he is a serial entrepreneur and has founded several companies positioned in health strategies and pharmaceutical product design.

Hervé Blottière, PhD, is Director of Research at INRAE. He is an expert in functional metagenomics and deciphering the molecular mechanisms of microbiota-host interactions. He is Scientific Director of the MetaFun platform at MetaGenoPolis (Jouy en Josas) and deputy-Director of the UMR 1280 INRAE PhAN “Pathophysiology of Nutritional Adaptations” in Nantes.

Joël Doré, PhD, is a world leader in human intestinal microbial ecology and specialist in metagenomics. He is Director of Research at the Micalis Institute (Université de Paris-Saclay, INRAE, AgroParisTech) and scientific director of the centre of excellence for microbiome analysis, MetaGenoPolis.

Olivier Tastet is an engineer with a degree in applied mathematics from the University of Paris 13. In 2009, Olivier founded the Canopee group, whose company Coperneec specializes in the field of artificial intelligence and operates alongside NovoBiome to build up a comprehensive AI approach from strategic watch (Natural Language Processing) to R&D process and discovery platform optimization (AI-powered microscopic image analysis).

Contact

NovoBiome
Pierre-Yves Mousset, Chief Executive Officer
+33 (0) 616 310 400
[email protected]

Consilium Strategic Communications
Amber Fennell, Jonathan Birt, Melissa Gardiner, Carina Jurs
+44 (0) 203 709 5000
[email protected]


1 LBPs are medicinal products containing living micro-organisms such as bacteria or yeasts, which have a positive influence on the health and physiology of the host. Source: Ph. Eur. Monograph 3053 (EDQM, 2019)
2 GlobalData

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

XtalPi Unveils XtalGazer: A Comprehensive AI-Driven Polymorph Selection Platform

Published

on

xtalpi-unveils-xtalgazer:-a-comprehensive-ai-driven-polymorph-selection-platform

CAMBRIDGE, Mass., March 28, 2024 /PRNewswire/ — XtalPi Inc., a leading global technology company in integrating artificial intelligence (AI) and robotics to advance the discovery of groundbreaking medicine and innovative materials, announced today the launch of its proprietary comprehensive solid form discovery and selection platform, XtalGazer. This advanced platform aims to significantly improve the polymorph selection process for the pharmaceutical industry by integrating AI- and automation-powered experimental and computational approaches.

XtalGazer provides a total solution for delivering high-quality polymorph screening and selection methods to expedite drug development and mitigate risks. It represents a paradigm shift in solid-state research, moving from the traditional trial-and-error approach to a data-driven, design-led methodology. The platform provides an expansive suite of foundational tools to accelerate polymorph discovery, characterization, and selection process, empowering pharmaceutical companies to conduct thorough research with less active pharmaceutical ingredient (API) in shorter development cycles.
A key component of XtalGazer is XtalCSP, a crystal structure prediction platform to perform global searches of crystal structures for target molecules and the other optional components in the corresponding searching space, offering a deep insight into possible stable forms. Furthermore, crystallization strategy recommendations will provide AI-backed experimental design to help avoid human bias. XtalGazer also utilizes MicroED to rapidly elucidate crystal structures from powder samples, reducing the need for growing single crystals.
XtalPi’s launch of XtalGazer marks another significant step in the company’s ongoing exploration of solid-state research. From crystal structure prediction platforms being one of the first products to launch at XtalPi, to today’s comprehensive polymorph selection platform, XtalPi will keep fulfilling its promise to solving challenging problems in this space. XtalPi will continue to deliver faster, more accurate, and more comprehensive approaches to building an ecosystem for the R&D process in solid-state, pre-formulation and crystallization.
For more information about XtalPi, please visit www.xtalpi.com.
About XtalPi:
XtalPi is an innovative technology company powered by artificial intelligence (AI) and robotics. Founded in 2015 on the MIT campus, XtalPi is dedicated to driving intelligent and digital transformation in the life science and new materials industries. With tightly interwoven quantum physics, AI, cloud computing, and large-scale clusters of robotic workstations, XtalPi offers a range of technology solutions, services, and products to accelerate and empower innovation for biopharmaceutical and new materials companies worldwide.
Media Contact: Vivienne [email protected]
Logo – https://mma.prnewswire.com/media/632519/XtalPi_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/xtalpi-unveils-xtalgazer-a-comprehensive-ai-driven-polymorph-selection-platform-302102794.html

Continue Reading

Artificial Intelligence

ICIS and Base Oil News Announce Partnership to Enhance Market Insights

Published

on

icis-and-base-oil-news-announce-partnership-to-enhance-market-insights

LONDON, March 28, 2024 /PRNewswire/ — ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News, a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market. This collaboration marks a significant milestone in the dissemination and exchange of critical market data and insights.

With more than two decades of journalism experience at Bloomberg, Reuters, and Argus Media, Iain Pocock brings unparalleled expertise to this partnership. His deep understanding of illiquid energy markets makes him a credible and influential figure in the industry. Since November 2023, Iain has been working closely with ICIS to share and exchange valuable data and insights, enhancing the services both platforms offer to the base oils and lubricants market.
Through the collaboration, Iain integrates ICIS’ extensive content and data resources in Base Oil News market coverage. In return, he contributes market insights to ICIS News, including expert and exclusive analysis of supply and demand dynamics, price margins, and other critical market drivers. This exchange ensures that subscribers of both ICIS and Base Oil News have access to the most comprehensive, timely, and accurate market information, empowering them to make informed decisions.
“It’s a very exciting partnership – where we leverage each other’s strengths and provide actionable insights to our customers,” said Iain Pocock, Founder of Base Oil News. “The market is the winner.”
“As ICIS is already the world’s most trusted pricing benchmark for base oils, this collaboration with Iain Pocock and Base Oil News provides an even stronger and deeper service to our customers,” said Stephen Burns, Editorial Director at ICIS. “Iain’s expertise and extensive industry connections are invaluable, and we have established a fruitful partnership that benefits the market at large.”
For the latest insights from Iain Pocock on ICIS News, visit ICIS News.  
About ICIS
ICIS – Independent Commodity Intelligence Services – helps businesses through seamlessly delivering data and analytics, across the chemical, fertilizer and energy markets. A trusted source and benchmark for price information and insight across key commodities markets worldwide. Our independent, transparent market intelligence informs thousands of quality decisions every day, taking the pressure out of negotiations and giving customers space for more innovative thinking, through published datasets including price assessments, price forecasts, supply and demand fundamentals and more.
Over 150 years of shaping the world by connecting markets to optimise the world’s valuable resources. With a global team of more than 600 experts, ICIS has employees based in London, New York, Houston, Karlsruhe, Milan, Mumbai, Singapore, Guangzhou, Beijing, Shanghai, Dubai, Sao Paulo, Seoul, Tokyo and Perth.
ICIS is part of RELX, a FTSE15 company with a market cap of £64bn and an employee base of over 30,000 experts across 40 countries.
About RELX
RELX is a global provider of information and analytics for professional and business customers across industries. The Group serves customers in more than 180 countries and has offices in about 40 countries. It employs approximately 30,000 people of whom almost half are in North America. RELX PLC is a London listed holding company which owns 52.9% of RELX Group. RELX NV is an Amsterdam listed holding company which owns 47.1% of RELX Group. The shares are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX and RENX. Total market capitalisation is approximately £64bn | €75bn | $81bn.
Logo: https://mma.prnewswire.com/media/619935/4277787/ICIS_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/icis-and-base-oil-news-announce-partnership-to-enhance-market-insights-302102782.html

Continue Reading

Artificial Intelligence

Trianz Welcomes Israel Abraham as Vice President of Services for Extrica.ai – The Data to AI Platform

Published

on

trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extrica.ai-–-the-data-to-ai-platform

SANTA CLARA, Calif., March 28, 2024 /PRNewswire/ — Digital transformation technology & services company Trianz is pleased to announce the appointment of Israel Abraham as Vice President of Extrica Platform Services.

Trianz has embarked on a transformative journey, redefining its value proposition with an ‘IP Led’ model, with a commitment to deliver the fastest time to value, lowest human dependence, and highest ROI. Central to this approach are our hyper-automated platforms, Concierto.Cloud, Extrica.AI, and Pulse, driving industry-leading transformations in cloud, data and analytics, AI, and the digital workplace.
Israel Abraham is a very well-known pioneer and industry leader in AI, data management, and analytics systems, with over three decades of experience. He joins as the services leader for Extrica- the Trianz Data to AI platform, which productizes data, provides data a face and purpose, and accelerates time to insights and AI by 50% or more. In the role of Extrica Services leader, Israel will lead the shaping, visioning, and delivery of Extrica.ai based enterprise wide datamesh, BI, and AI solutions for customers worldwide.
“We are thrilled to welcome Israel Abraham to the Trianz family,” said Sri Manchala, CEO of Trianz and author of Crossing the Digital Faultline. “He is a leader in modernization as well as conceptualization of data platforms anew. Israel’s prior background in the industry with financial services and insurance giants underscores our commitment to securing top-tier talent that brings real-world experiences and needs to our technology platforms. As we continue to broaden our footprint in the digital transformation space, Israel’s visionary leadership and practical experience will serve as the cornerstone in accelerating insights and AI to deliver transformative value to our clients.”
Having played pivotal roles in highly reputed and large organizations such as Liberty Mutual Insurance, MassMutual, Safeco, and CNA Insurance, Israel has garnered recognition as a seasoned leader in big data and AI cloud implementations. His accolades include the prestigious 2014 Ventana Research IT Innovation Award, the 2009 Informatica MDM Innovation Award, and three filed Data Engineering patents in the last four years.
“Trianz has been at the forefront of digital innovation, and Extrica.ai is a paradigm shifting data to AI platform that completely changes how analytics and AI are delivered- much faster, taking business ahead of change. I am excited to scale the adoption of the Extrica platform, which has attracted attention from giants across the industry and hyperscalers,” said Israel Abraham. “I look forward to engaging with customers, bringing my own experiences, and collaborating with the talented team at Trianz to further enhance the capabilities of the Extrica Platform Services to transform data & AI strategies, execution, and outcomes for customers.”
About Trianz
Trianz is a leading-edge technology platforms and services company that accelerates digital transformations at Fortune 100 and emerging companies worldwide in data & analytics, digital experiences, cloud infrastructure, and security. Our ‘IP Led Transformations’ approach, informed by insights from a recent global study spanning 20+ industries and 5000+ companies, addresses challenges posed by the rapid pace of AI-driven transformation, digital talent scarcity, and economic uncertainty. Our IP and platforms, including Concierto, Extrica, and Pulse, revolutionize cloud adoption, data analytics, and AI insights, empowering organizations to navigate the complexities of digital transformation seamlessly.
Founded in California and with an organization of over 2,000 associates across the United States and India, Trianz is a Premier Partner of AWS, consistently rated #1 by clients for value delivery over the past five years. Trianz has been ranked as one of the best Consulting Firms by Forbes and has been certified as a Great Place to Work for three years in a row. To learn more about Trianz, email [email protected] or visit www.trianz.com.
Watch Trianz CEO Sri Manchala’s insightful interview with Bloomberg on Partner | Crossing The Digital Faultline & Leading Towards Transformative Success – YouTube and delve deeper into his book Crossing the Digital Faultline at Crossing the Digital Faultline | Trianz.
Trianz Media [email protected] +1-408-387-5800
Logo: https://mma.prnewswire.com/media/626944/1199800/Trianz_Logo.jpg
 

View original content:https://www.prnewswire.co.uk/news-releases/trianz-welcomes-israel-abraham-as-vice-president-of-services-for-extricaai–the-data-to-ai-platform-302102589.html

Continue Reading
Advertisement

Latest News

Trending